UBS Downgrades Legend Biotech to Neutral, Lowers Price Target to $28
Benzinga Newsdesk 3 months ago
NewsDowngradesAnalyst RatingsPrice Target
UBS analyst Ashwani Verma downgrades Legend Biotech (NASDAQ:LEGN) from Buy to Neutral and lowers the price target from $49 to $28.
UBS analyst Ashwani Verma downgrades Legend Biotech (NASDAQ:LEGN) from Buy to Neutral and lowers the price target from $49 to $28.